Friday, 16 October 2026European Markets

SOLSTAD OFFSHORE Stock Bearish Momentum With A 34% Drop In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of SOLSTAD OFFSHORE (Oslo Børs Benchmark Index_GI: SOFF.OL) slid by a staggering 34.92% in 21 sessions from kr47.2 to kr30.72 at 10:30 EST on Wednesday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is falling 0.67% to kr1,193.32, after five successive sessions in a row of gains.

SOLSTAD OFFSHORE's last close was kr32.22, 38.04% below its 52-week high of kr52.00.

About SOLSTAD OFFSHORE

Solstad Offshore ASA operates offshore service and construction vessels for offshore and renewable energy industry worldwide. It provides platform supply vessel, anchor handling vessel, subsea construction, and renewable energy services. The company offers subsea construction and renewable energy services, such as geotechnical work, walk to work services, grouting, SURF operations, deep sea mining, cable laying and repair, trenching and burial, ROV support, installation of subsea equipment, survey work, IMR operations, node seismic operations, and diving and topside maintenance work. It operates a fleet of 25 construction service vessels, 26 anchor handling tug support vessels, and 45 platform supply vessels. The company was founded in 1964 and is headquartered in Skudeneshavn, Norway.

Earnings Per Share

As for profitability, SOLSTAD OFFSHORE has a trailing twelve months EPS of kr24773.9.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -46.02%.

Moving Average

SOLSTAD OFFSHORE's value is way under its 50-day moving average of kr41.03 and under its 200-day moving average of kr31.50.

Sales Growth

SOLSTAD OFFSHORE's sales growth for the current quarter is 25.7%.

More news about SOLSTAD OFFSHORE (SOFF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com